The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

The Austrian drug development company, Savira Pharmaceuticals, has granted Roche exclusive, worldwide rights to a small molecule programme where the goal is to use inhibition of the influenza polymerase as a promising target for novel anti-influenza drugs. Savira, founded in 2009, will receive an undisclosed upfront payment and research and development support, and is eligible for up to EUR240 million in milestones, plus royalties.

Start-Up showcases these recently launched companies: CFD Therapeutics, Heartscape Technologies, onepharm, Sorbent Therapeutics.